hydrocotarnine has been researched along with Pain in 3 studies
hydrocotarnine: RN given refers to parent cpd; structure in Merck, 9th ed, #4679
Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In Japan, although oral oxycodone is widely used for cancer pain treatment, there is no injection preparation of oxycodone used as a single ingredient." | 7.78 | [Retrospective study on intravenous compound injection of cancer pain patients with oxycodone and hydrocotarnine preparation in comparison with subcutaneous administration]. ( Akagi, T; Kudo, N; Matoba, M; Miura, K; Murakami, S; Saito, O; Sano, T; Shuto, C; Yamamoto, H; Yokote, N, 2012) |
| "Compound injections of oxycodone and hydrocotarnine are currently used as one of the treatment options for some cases with cancer pain." | 7.74 | Pharmacokinetics and variation in the clearance of oxycodone and hydrocotarnine in patients with cancer pain. ( Fukawa, M; Hoka, S; Kokubun, H; Matoba, M; Yago, K; Yamada, Y, 2007) |
| "The demand for oxycodone increases in the treatment of patients with cancer pain, but there is no injection formulation containing oxycodone as a single ingredient in Japan." | 7.74 | [Conversion ratio between intravenous oxycodone/hydrocotarnine and sustained-release oral oxycodone in patients with cancer pain]. ( Fukawa, M; Hoka, S; Kokubun, H; Matoba, M; Nakamura, K; Yago, K, 2007) |
| "In Japan, although oral oxycodone is widely used for cancer pain treatment, there is no injection preparation of oxycodone used as a single ingredient." | 3.78 | [Retrospective study on intravenous compound injection of cancer pain patients with oxycodone and hydrocotarnine preparation in comparison with subcutaneous administration]. ( Akagi, T; Kudo, N; Matoba, M; Miura, K; Murakami, S; Saito, O; Sano, T; Shuto, C; Yamamoto, H; Yokote, N, 2012) |
| "Compound injections of oxycodone and hydrocotarnine are currently used as one of the treatment options for some cases with cancer pain." | 3.74 | Pharmacokinetics and variation in the clearance of oxycodone and hydrocotarnine in patients with cancer pain. ( Fukawa, M; Hoka, S; Kokubun, H; Matoba, M; Yago, K; Yamada, Y, 2007) |
| "The demand for oxycodone increases in the treatment of patients with cancer pain, but there is no injection formulation containing oxycodone as a single ingredient in Japan." | 3.74 | [Conversion ratio between intravenous oxycodone/hydrocotarnine and sustained-release oral oxycodone in patients with cancer pain]. ( Fukawa, M; Hoka, S; Kokubun, H; Matoba, M; Nakamura, K; Yago, K, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sano, T | 1 |
| Akagi, T | 1 |
| Yokote, N | 1 |
| Shuto, C | 1 |
| Kudo, N | 1 |
| Miura, K | 1 |
| Murakami, S | 1 |
| Saito, O | 1 |
| Yamamoto, H | 1 |
| Matoba, M | 3 |
| Kokubun, H | 2 |
| Fukawa, M | 2 |
| Hoka, S | 2 |
| Yamada, Y | 1 |
| Yago, K | 2 |
| Nakamura, K | 1 |
3 other studies available for hydrocotarnine and Pain
| Article | Year |
|---|---|
[Retrospective study on intravenous compound injection of cancer pain patients with oxycodone and hydrocotarnine preparation in comparison with subcutaneous administration].
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Child; Ch | 2012 |
Pharmacokinetics and variation in the clearance of oxycodone and hydrocotarnine in patients with cancer pain.
Topics: Adult; Aged; Analgesics, Opioid; Female; Humans; Infusions, Intravenous; Logistic Models; Male; Meta | 2007 |
[Conversion ratio between intravenous oxycodone/hydrocotarnine and sustained-release oral oxycodone in patients with cancer pain].
Topics: Administration, Oral; Adolescent; Adult; Aged; Analgesics, Opioid; Delayed-Action Preparations; Fema | 2007 |